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Embryonic	   stem	   cells	   (ES	   cells)	   have	   two	   principal	   characteris=cs:	   they	   can	   divide	   themselves	  
indeﬁnitely	  and	  have	   the	  ability	   to	  diﬀeren=ate	   in	  any	  cell	   type.	  Obtaining	   these	  cells	   trigger	  an	  
ethical	  debate	  because	  the	  destruc=on	  of	  a	  human	  embryo	  is	  needed.	  That’s	  the	  reason	  why	  new	  
technologies	  have	  obtain	  pluripotent	   cells	  by	   reprograming	   soma=c	  cells:	   these	  cells	  are	  named	  
induced	  pluripotent	  stem	  cells	  (iPS	  cells).	  	  	  
!  Iden=fy	  what	  iPS	  cells	  are	  and	  how	  we	  can	  obtain	  them	  
!  Describe	  the	  role	  of	  inducing	  reprograming	  factors	  (OSKM)	  
!  Compare	  characteris=cs	  between	  embryonic	  stem	  cells,	  tumour	  cells	  and	  iPS	  cells	  
!  Men=on	  applica=ons	  and	  medical	  uses	  of	  iPS	  cells	  
	  	  
Objec=ves	  
iPS	  cells	  are	  soma=c	  cells,	  which	  have	  been	  reprogramed	  by	  the	  
overexpression	  of	  deﬁned	  factors:	  OSKM	  
OSKM	  factors	  can	  be	  introduced	  into	  cells	  by	  diﬀerent	  methods:	  
OSKM	   factors	  bind	  diﬀerent	  promoters	  
and	   enhancers	   causing	   epigene8c	  
changes	   in	   histones.	   Genes	   involved	   in	  
cell	   phenotype	   are	   silenced	   and	  





Unfortunately,	   reprograming	   eﬃciency	  
is	  low;	  a	  matura8on	  process	  is	  required	  
to	   acquire	   a	   total	   expression	   of	  
pluripotency	  marks.	  
!  iPS	  cells,	  which	  come	  from	  reprograming	  processes	  of	  soma=c	  cells,	  are	  a	  viable	  alterna=ve	  to	  
embryonic	  stem	  cells,	  without	  ethical	  implica=ons.	  
!  These	  new	  cells	  open	  the	  door	  to	  new	  perspec=ves	  into	  biomedicine	  and	  regenera=ve	  
medicine,	  but	  also	  to	  basic	  research	  and	  molecular	  studies	  of	  diseases.	  
!  Current	  research	  in	  this	  ﬁeld	  is	  very	  ac=ve.	  There	  are	  s=ll	  many	  things	  to	  solve,	  especially	  to	  
prevent	  the	  tumour	  poten=al	  of	  iPS	  cells.	  
*OSKM:	  Oct	  3/4,	  Sox2,	  Klf-­‐4	  i	  c-­‐Myc	   Fig.1	  Experimental	  approach	  to	  nuclear	  reprogramming.	  (Jullien	  et	  at,	  2011)	  	  
Fig.	  2	  Epigenome	  remodelling	  by	  OSKM	  factors	  
(Burganim	  et	  al.	  2013)	  
Fig.	  3	  Human	  iPS	  cells	  applica8ons	  
(Adapted	  from	  Bellin	  et	  al.	  2012)	  
	  
	  











Soma=c	  cells	  	  
iPS	  cells	   Specialized	  
diﬀeren=ated	  cells	  
There	  exist	  mul=ple	  and	  advantageous	  applica=ons	  of	  
iPS	  cells,	  both	  in	  basic	  research	  and	  medical	  uses.	  	  
	  
!  Cells	  from	  any	  8ssue	  in	  the	  body,	  even	  from	  
diﬃcult	   access	   organs,	   such	   as	   neurons	   or	  
cardiomyocytes	  can	  be	  obtained.	  	  
!  They	   allow	   to	   reduce	   the	   genera=on	   of	  
animal	  models	  
!  Studies	  of	  human	  pathologies	  become	  more	  
reliable	  
!  New	   drug	   tests	   with	   pa=ent-­‐derived	   cells	  
can	  be	  performed	  in	  preclinical	  trials	  	  
!  Wai=ng	   periods	   and	   donors	   for	   organ	   and	  
8ssue	  transplants	  can	  be	  reduced	  	  
!  They	  do	  not	  show	  immunological	  rejec8on	  	  
The	  main	   objec=ve	   of	   genera=ng	   iPS	   cells	   is	   obtaining	   cells	   as	   similar	   as	   possible	  
with	  ES	  cells.	  Although	  many	  characteris=cs	  are	  alike	  between	  these	  two	  types	  of	  
pluripotent	  cells,	  iPS	  cells	  show	  some	  Epigene8c	  memory	  that	  can	  disturb	  in	  further	  
applica=ons.	   In	  addi=on,	   iPS	   cells	   also	   share	   some	   traits	  with	   tumour	   cells,	  which	  
contribute	  to	  complica=ons	  in	  medical	  uses.	  	  
Competences	  shared	  with	  ES	  cells	  
!  Chroma=n	  structure	  
!  Methyla=on	  pamern	  
!  Gene	  expression	  
!  Pluripotency	  
Competences	  shared	  with	  tumour	  cells	  
!  High	  prolifera=on	  
!  Genomic	  instability	  (causing	  
muta=ons	  and	  chromosome	  
aberra=ons)	  
